Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
As part of Une Jonquille contre le Cancer 2025, which takes place across France from March 11 to 23, pastry chef Jessica ...
A study led by the UNIGE and the HUG shows that an interval of at least 50 days between stopping immunotherapy and liver transplantation significantly reduces the risk of rejection.